Vir Biotechnology, Inc. (VIR)
收市後：
- Zacks
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Insider Monkey
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript May 3, 2024 Vir Biotechnology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello. Welcome to Vir Biotechnology’s First Quarter 2024 Financial Results and Business Update Call. As a reminder, […]
- Zacks
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
